Home PR Newswire
Saturday, August 15, 2026
25.1
C
Bengaluru
Hot topics
Healthcare Disruption – Will Ola, Swiggy, Pharmaeasy, and Hospitals Converge to Deliver Health Care on Call at Your Doorstep?
How long before digital Unicorns like Ola, Swiggy, Pharmeasy, and many others realize the humongous opportunity of delivering health care at the doorstep?
Imagine an app like Ola, where instead of entering where you want to go, you enter the nature of your medical need/emergency and search and find a range of hospitals/doctors/paramedics who can act as the first responders and reach your home in an ambulance or a motorbike with an HCP as a pillion rider with all necessary equipment from the thermometer to defibrillator depending on the nature of the medical care needed and triage and route you/your loved ones to the nearest hospital with an indicative cost of treatment in partnership with health insurance companies?
Tariffs and Indian Generics: Is Trump Cutting His Nose to Spite His Face?
Trump’s Tariffs Threaten US Drug Affordability The Value of...
Healthcare Isn’t Working As Well As It Should – A Brief Summary Of The ZS Report 2024
The ZS report discusses how people feel about healthcare...
American Tariffs and The Rise of the Corporate Superpower
From Nation-States to Corporate Titans: How Innovation is Redrawing...
Digital in Pharma and RoI – What and How to Measure Metrics that Matter
To be able to measure the RoI on digital in pharma, it is necessary to understand customers as individuals and create newer segmentation based on these needs and interests. This calls for the NextGen RCPA of data collection and personalized communications that engage customers, based on which pharma must create customer experiences that matter to them.
If your content does not scratch, where it itches the customers, digital or phygital, customers will not feel at home (comfortable, delighted, and wants more), which is what matters. Not a digital euphoria, which will soon die down as customers simply ignore it as they did when pharma launched a plethora of webinars.
Will President Trump’s Diktat Improve Drug Quality For Indian Patients?
Executive Summary
The geopolitical landscape of pharmaceutical manufacturing is shifting...
Mounjaro is the Exceptional Growth Story: Ranks #1
The July Brand Monitor by Pharmarack shows a healthy...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...
With extensive experience across commercial excellence, analytics, insights, AI-driven...
Will President Trump’s Diktat Improve Drug Quality For Indian Patients?
Executive Summary
The geopolitical landscape of pharmaceutical manufacturing is shifting...
Mounjaro is the Exceptional Growth Story: Ranks #1
The July Brand Monitor by Pharmarack shows a healthy...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...
With extensive experience across commercial excellence, analytics, insights, AI-driven...
Will President Trump’s Diktat Improve Drug Quality For Indian Patients?
Executive Summary
The geopolitical landscape of pharmaceutical manufacturing is shifting...
Mounjaro is the Exceptional Growth Story: Ranks #1
The July Brand Monitor by Pharmarack shows a healthy...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...
With extensive experience across commercial excellence, analytics, insights, AI-driven...
Will President Trump’s Diktat Improve Drug Quality For Indian Patients?
Executive Summary
The geopolitical landscape of pharmaceutical manufacturing is shifting...
Mounjaro is the Exceptional Growth Story: Ranks #1
The July Brand Monitor by Pharmarack shows a healthy...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...
With extensive experience across commercial excellence, analytics, insights, AI-driven...
Hot topics
Subhendu K Datta has taken on a new role as Senior Vice President (Sales & Marketing) – India & Nepal SBU Head at Micro...
In his new position, he will lead teams across...
Finding the middle ground for Doctor-Stakeholder Relationship
Healthcare systems around the world differ – public, private or a mix of both public and private (like in India). With all the variance in healthcare delivery models, the risks to healthcare professionals remain universal: needle injuries to litigations to episodes of threats/ violence
Novo Nordisk’s Big Reset: What 9,000 Job Cuts Signal for Pharma’s Future
For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged.
But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.
Five Disruptive Forces Shaking Up Indian Pharma
A curtain raiser on disruptions that will permanently alter the pharma marketing landscape in the near future.
Healthcare Isn’t Working As Well As It Should – A Brief Summary Of The ZS Report 2024
The ZS report discusses how people feel about healthcare...
Will President Trump’s Diktat Improve Drug Quality For Indian Patients?
Executive Summary
The geopolitical landscape of pharmaceutical manufacturing is shifting...
Mounjaro is the Exceptional Growth Story: Ranks #1
The July Brand Monitor by Pharmarack shows a healthy...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...
With extensive experience across commercial excellence, analytics, insights, AI-driven...
Will President Trump’s Diktat Improve Drug Quality For Indian Patients?
Executive Summary
The geopolitical landscape of pharmaceutical manufacturing is shifting...
Mounjaro is the Exceptional Growth Story: Ranks #1
The July Brand Monitor by Pharmarack shows a healthy...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...
With extensive experience across commercial excellence, analytics, insights, AI-driven...
Will President Trump’s Diktat Improve Drug Quality For Indian Patients?
Executive Summary
The geopolitical landscape of pharmaceutical manufacturing is shifting...
Mounjaro is the Exceptional Growth Story: Ranks #1
The July Brand Monitor by Pharmarack shows a healthy...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...
With extensive experience across commercial excellence, analytics, insights, AI-driven...
Will President Trump’s Diktat Improve Drug Quality For Indian Patients?
Executive Summary
The geopolitical landscape of pharmaceutical manufacturing is shifting...
Mounjaro is the Exceptional Growth Story: Ranks #1
The July Brand Monitor by Pharmarack shows a healthy...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability...
With extensive experience across commercial excellence, analytics, insights, AI-driven...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Will President Trump’s Diktat Improve Drug Quality For Indian Patients?
Executive Summary
The geopolitical landscape of pharmaceutical manufacturing is shifting...
Mounjaro is the Exceptional Growth Story: Ranks #1
The July Brand Monitor by Pharmarack shows a healthy...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
Newsletter
Get important news delivered directly to your inbox and stay connected!